Considerations for Treatment of PSMA-Staged High-Risk Patients in Community Practice
This activity discusses the use of PSMA PET for staging in high-risk prostate cancer. This includes when to order a PSMA PET, how to interpret it, common pitfalls and controversies of the scans. The discussion is framed around the patient groups that will be better defined within high-risk prostate cancer, that is, localized disease, node positive, and oligometastatic prostate cancer patients. Within these patient populations we further discuss issues about genomics, nodal radiation, ADT type and duration, fractionation and boost schedules and stereotactic treatment of oligomets.
- PSMA PET Staging: Does This Change Everything?
Jeremy de Leon, MBBS, FRANZCR
- Treatment of Local Regional Disease in the Era of PSMA PET Staging
Leslie K. Ballas, MD
- Approach to Prostate Oligometastasis in the PSMA-PET Era
Evan Marshall Thomas, MD, PhD
- Q and A
Thomas P. Boike, MD, FASTRO, MMM - Moderator
This activity is available from September 19, 2023, through 11:59 p.m. Eastern time on September 18, 2025.
This activity was originally recorded at the 2022 ASTRO Annual Meeting.
The activity is designed to meet the interests of radiation oncologists and residents.
Upon completion of this activity, participants should be able to:
- Explain the benefits and controversies when considering PSMA PET staging for high-risk prostate cancer patients.
- Determine how current evidence for treatment applies to patients when staged with PSMA PET scans.
Thomas P. Boike, MD, FASTRO, MMM, is employed by GenesisCare USA/Michigan Healthcare Professionals. Dr. Boike receives honoraria from the following entities: ASTRO APEx, Medivation/Astellas, Janssen, Boston Scientific, Blue Earth Diagnostics, Elekta, AstraZeneca, Lantheus, Palette Life Sciences, Myovant and Pfizer. Dr. Boike serves in a leadership role with the following entities: ASTRO APEx Committee (Co-Chair), NCI Prostate Cancer Task Force (Member), and Michigan Institute of Urology Foundation (Board Member).
Jeremy de Leon, MBBS, FRANZCR is employed by GenesisCare St. Vincent’s Clinic.
Leslie K. Ballas, MD, is employed by University of Southern California, Keck School of Medicine, Department of Radiation Oncology. Dr. Ballas also receives compensation from Cedars Sinai.
Evan Marshall Thomas, MD, PhD, is employed by The Ohio State University Wexner Medical Center, Department of Radiation Oncology. Dr. Thomas receives research funding from Varian.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until September 18, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.